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Abstract
Background: The aim of this study was to compare the pharmacokinetic properties of sodium
ibuprofen and ibuprofen acid incorporating poloxamer with standard ibuprofen acid tablets.
Methods: Twenty-two healthy volunteers were enrolled into this randomised, single-dose, 3-way
crossover, open-label, single-centre, pharmacokinetic study. After 14 hours' fasting, participants
received a single dose of 2 × 200 mg ibuprofen acid tablets (standard ibuprofen), 2 × 256 mg
ibuprofen sodium dihydrate tablets (sodium ibuprofen; each equivalent to 200 mg ibuprofen acid)
and 2 × 200 mg ibuprofen acid incorporating 60 mg poloxamer 407 (ibuprofen/poloxamer). A
washout period of 2-7 days separated consecutive dosing days. On each of the 3 treatment days,
blood samples were collected post dose for pharmacokinetic analyses and any adverse events
recorded. Plasma concentration of ibuprofen was assessed using a liquid chromatographic-mass
spectrometry procedure in negative ion mode. A standard statistical ANOVA model, appropriate
for bioequivalence studies, was used and ratios of 90% confidence intervals (CIs) were calculated.
Results: Tmax for sodium ibuprofen was less than half that of standard ibuprofen (median 35 min
vs 90 min, respectively; P = 0.0002) and Cmax was significantly higher (41.47 μg/mL vs 31.88 μg/mL;
ratio test/reference = 130.06%, 90% CI 118.86-142.32%). Ibuprofen/poloxamer was bioequivalent
to the standard ibuprofen formulation, despite its Tmax being on average 20 minutes shorter than
standard ibuprofen (median 75 mins vs 90 mins, respectively; P = 0.1913), as the ratio of test/
reference = 110.48% (CI 100.96-120.89%), which fell within the 80-125% limit of the CPMP and
FDA guidelines for bioequivalence. The overall extent of absorption was similar for the three
formulations, which were all well tolerated.
Conclusion: In terms of Tmax, ibuprofen formulated as a sodium salt was absorbed twice as quickly
as from standard ibuprofen acid. The addition of poloxamer to ibuprofen acid did not significantly
affect absorption.
Background
Ibuprofen [(±)-(R, S)-2-4(4-isobutylphenyl)-propionic
acid], a chiral 2-arylpropionic acid derivative non-steroi-
dal anti-inflammatory drug, is a widely used and well-tol-
erated analgesic [1]. Although ibuprofen is a non-selective
cyclooxygenase (COX) inhibitor, inhibiting both COX-1
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and COX-2 forms, its analgesic, antipyretic and anti-
inflammatory effects are achieved principally through
COX-2 inhibition [2].
With most analgesics, including ibuprofen, the initial rise
in plasma concentration following oral administration is
a key factor in determining the time to onset of pain relief
[3]. Ibuprofen is rapidly absorbed, and both peak plasma
concentrations and maximal analgesic onset are achieved
within 1.5-2 hours of oral administration [4].
Key pharmacokinetic studies have demonstrated that
there is a linear dose-response relationship between the
amount of drug administered and the area under the
serum concentration-time curve (AUC) following single
doses of ibuprofen (200-800 mg) [4]. There is also a sig-
nificant correlation between plasma ibuprofen levels and
the resultant degree of pain relief, particularly 1 hour after
administration [5].
For orally administered standard ibuprofen formulations,
it is desirable to have a formulation with a rapid rate of
absorption because this is required for rapid pain relief
[6]. It is well documented that ibuprofen salts, such as
ibuprofen lysine and ibuprofen arginate, are more rapidly
absorbed than formulations of free ibuprofen acid [7,8].
Another ibuprofen salt, sodium ibuprofen dihydrate (ibu-
profen sodium), manufactured by Hoffmann-La Roche
Ltd, was recently shown to be bioequivalent to the lysine
and arginate salt forms. Several studies have shown that
faster-absorbed formulations lead to faster onset of anal-
gesia [9-14].
Reckitt Benckiser Healthcare International (Hull, UK) has
also developed ibuprofen formulations that are expected
to be absorbed faster than standard ibuprofen acid. The
first is a sodium ibuprofen formulation containing 256
mg of ibuprofen sodium dihydrate per tablet (equivalent
to 200 mg ibuprofen acid). The second test ibuprofen for-
mulation contains 200 mg ibuprofen acid plus 60 mg of
the surfactant poloxamer 407 (from the poloxamer family
of polymeric non-ionic surface active agents) to increase
the rate of dissolution of the tablet and therefore enable
more rapid absorption. Poloxamers have been used previ-
ously to enhance dissolution and bioavailability of poorly
water-soluble drugs, including ibuprofen [15].
The aim of this phase I study was to compare the pharma-
cokinetic properties of a single dose (2 tablets) of each of
the two test formulations with those of standard ibupro-
fen (2 × 200 mg tablets) in healthy volunteers, in order to
add to the growing body of evidence for the faster absorp-
tion rates of alternative ibuprofen formulations.
This study was conducted in accordance with the Declara-
tion of Helsinki [16], as referenced in EU Directive 2001/
20/EC3 [17] and complies with International Conference
on Harmonisation, Good Clinical Practice and applicable
regulatory requirements.
Methods
The study protocol, together with participant information
and consent documents, were reviewed and approved by
South East Wales Local Research Ethics Committee.
Participants
Healthy male and female volunteers 18-50 years of age
(mean 27.2 years) and with a body mass index (BMI) of
20-27 kg/m2 (mean 24.1 kg/m2) were included in the
study. Participants had provided written informed con-
sent.
Participants with a history of significant disease, any con-
dition that might have interfered with the absorption, dis-
tribution, metabolism or excretion of the drugs, or a
history of allergy or migraine were ineligible for the study.
Those with a history of gastrointestinal disorders, cardiac
disease or hypertension, or of psychotic illness were ineli-
gible. Participants reporting frequent dyspepsia, smoking
in the previous 6 months and those with a history of drug
misuse (including alcohol) were excluded from the study.
Participants who had ingested a prescribed drug at any
time within the 14 days preceding study enrolment
(excluding hormonal contraceptives and hormone
replacement therapy) or an over-the-counter (OTC) prep-
aration within 7 days preceding enrolment were also
excluded, as were those who had donated blood in the 12
weeks preceding enrolment.
Further exclusion criteria included: known risk factors for
AIDS or known HIV positive status, a positive viral serol-
ogy screen; those with clinically significant abnormal lab-
oratory values at screening; women of childbearing
potential, who were pregnant or lactating, seeking preg-
nancy or failing to take adequate contraceptive precau-
tions; those unable in the opinion of the investigator to
comply fully with the study requirements; those previ-
ously randomised into the study; previous randomisation
in the study or participation in a clinical trial in the previ-
ous 12 weeks; citizens of the United States of America and
participants of any nationality who were not resident in
the UK at the time of the study.
Study design
This study was a randomised, 3-way crossover, open-
label, single-centre, pharmacokinetic study to compare
the rate of absorption (assessed from pharmacokineticBMC Clinical Pharmacology 2009, 9:19 http://www.biomedcentral.com/1472-6904/9/19
Page 3 of 10
(page number not for citation purposes)
parameters) of one standard and two test formulations of
ibuprofen given in single doses.
Participants received a single dose of 2 × 200 mg ibupro-
fen acid tablets (standard ibuprofen; Nurofen® [Reckitt
Benckiser Healthcare, UK]), 2 × 256 mg ibuprofen sodium
dihydrate tablets (sodium ibuprofen; each equivalent to
200 mg ibuprofen acid) and 2 × 200 mg ibuprofen acid
tablets each incorporating 60 mg poloxamer 407 (ibupro-
fen/poloxamer). A washout period of 2-7 days separated
consecutive dosing days.
Participants attended an initial screening visit followed by
three treatment visits, each of which required the partici-
pants to stay overnight and fast for 14 hours. A post-study
follow-up visit occurred 2-7 days after the final treatment
visit.
Alcohol consumption was limited to two units/day in the
7 days before the screening visit and participants were
required not to drink alcohol from 48 hours before
admission to the end of each treatment visit (i.e. until
after the 12-hour blood sample). Caffeine intake was pro-
hibited during the study.
Assessments
A serum pregnancy test was conducted at the initial
screening visit and at each treatment visit if appropriate. A
urine sample was collected at each of the five visits for (1)
urinalysis at the screening and post-study follow-up visits
and (2) for drugs of misuse and alcohol at the pre-study
visit and at each treatment visit. Haematology and bio-
chemistry assessments were conducted at the screening
visit and the post-study visit. On the three treatment days,
blood samples (5 ml) were collected from all participants
at 5, 10, 15, 20, 25, 30, 35, 40, 50 minutes and 1, 1.25,
1.5, 1.75, 2, 3, 6, 9 and 12 hours post dose for pharmacok-
inetic analyses. More frequent sampling was conducted in
the first hour to obtain accurate pharmacokinetic data
during the initial absorption phase.
Safety was assessed in terms of the overall number of par-
ticipants with adverse events. Adverse events were
recorded in the case report forms by the investigator or
designee after asking participants "Have you experienced
any symptoms or complaints?" before dosing, at 4 and 12
hours post dose, prior to the subject leaving the unit, and
again when the subject returned to the unit for their next
visit. Spontaneously reported adverse events were also
recorded, and laboratory values and vital signs were mon-
itored.
Plasma ibuprofen determination
Plasma ibuprofen determinations were performed by
Simbec Research Limited using a liquid chromatographic-
mass spectrometry procedure (LC-MS) in negative ion
mode. This procedure was fully validated over the calibra-
tion range 0.5-100 μg/ml and a limit of quantitation set at
0.5 μg/ml. Volumes of 0.2 ml of test, standard and quality
control sample were spiked with 50 μg flurbiprofen inter-
nal standard (i.e. 250 μg/ml) in acetonitrile to facilitate
protein precipitation from the plasma. After centrifuga-
tion, the supernatant was evaporated to dryness and
reconstituted in assay mobile phase. LC-MS analysis of
extract was performed on a 5 μm C18 column (5 cm ×
0.21 cm) with mass detection by a PE-Sciex API 150EX
single quadrupole mass spectrometer under the following
conditions:
Mobile Phase:  0.01 M ammonium acetate (49.95% v/v):
acetonitrile (49.95% v/v): glacial acetic acid (0.10% v/v)
Flow Rate:  0.3 ml/min
Split Ratio:  1:5
Data acquisition and integration were achieved using a
Macintosh computer system running PE Sciex Masschrom
version 1.1.1 data handling software incorporating MAC-
QUAN version 1.6 software.
Study endpoints
The primary endpoints were the pharmacokinetic varia-
bles Tmax, Cmax, AUC0-t and AUC0-inf (Table 1) derived
from the plasma ibuprofen concentrations for the three
formulations. As a secondary pharmacokinetic endpoint,
the cumulative AUCs at each blood sampling time point
up to 1 hour after dosing were compared in order to fully
Table 1: Pharmacokinetic variables and their definitions
Tmax The time to the first occurrence of the maximum plasma concentration
Cmax The observed maximum plasma concentration
AUC0-t AUC to the last measurable plasma concentration (Cp), calculated by the linear trapezoidal rule
AUC0-inf AUC calculated by linear trapezoidal rule to the last measurable Cp with additional area calculated from Cp/Kel. Kel is the 
elimination rate constant calculated from the slope of the terminal portion of the plasma profile calculated by least-squares 
regression of log (concentration) against timeBMC Clinical Pharmacology 2009, 9:19 http://www.biomedcentral.com/1472-6904/9/19
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Mean plasma ibuprofen concentrations (μg/mL) Figure 1
Mean plasma ibuprofen concentrations (μg/mL).
Table 2: Cmax, AUC0-t, AUC0-inf and Tmax data
Sodium ibuprofen
(n = 22)
Ibuprofen/poloxamer
(n = 22)
Standard ibuprofen
(n = 22)
Cmax (μg/mL)
Arithmetic mean 43.01 36.06 32.84
Geometric LS mean 41.47 35.22 31.88
AUC0-t (μg/mL/h)
Arithmetic mean 120.57 124.10 119.10
Geometric LS mean 117.79 120.55 115.28
AUC0-inf (μg/mL/h)
Arithmetic mean 122.88 126.72 121.99
Geometric LS mean 119.73 122.75 117.71
Tmax (min)
Median 35 75 90
LS: least-squaresBMC Clinical Pharmacology 2009, 9:19 http://www.biomedcentral.com/1472-6904/9/19
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explore any differences in the rate of drug absorption
between the three formulations.
Sample size determination
The sample size of this study was based on previous work
with other similarly fast-absorbed ibuprofen formulations
in which the within-subject coefficient of variation for
ibuprofen Cmax was found to be 20%. Therefore, using the
method of Diletti et al. [18], a sample size of 20 subjects
was considered sufficient to detect a 20% difference
between the test and reference formulations with a power
of 80% and alpha of 5%, based upon a test versus refer-
ence ratio of 1.05. Since the main parameter of interest in
this study was Tmax, the sample size calculation was also
based on Tmax. The within-subject standard deviation for
Tmax in the previous studies was found to be approxi-
mately 70 minutes. In order to detect a difference of 40
minutes in Tmax between the test and reference formula-
tions, it was calculated that a sample size of 20 subjects
would be required to give a power of 85%. Furthermore,
the sample size of this study was in line with that used in
similar published studies [19].
Statistical analyses
Tmax was analysed using a Wilcoxon matched pairs test. A
95% non-parametric confidence interval (CI) was con-
structed for the median difference in the Tmax values based
on the Hodges-Lehmann estimates.
For the cumulative AUC, AUC0-t, AUC0-inf and Cmax data,
analysis of variance, including the terms for sequence,
subject nested within sequence, period and formulation,
was carried out on logarithmically transformed data.
Point estimates and 90% CIs for the difference between
each test treatment and the reference treatment were con-
structed and then back transformed to give estimates of
the ratio of the geometric least squares means and 90%
CIs for the ratios.
Results
Demographics
A total of 22 participants (15 males and 7 females) quali-
fied for enrolment and were randomised to treatment.
The mean age of all participants was 27.2 years and the
Spaghetti plot of Tmax Figure 2
Spaghetti plot of Tmax.BMC Clinical Pharmacology 2009, 9:19 http://www.biomedcentral.com/1472-6904/9/19
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mean BMI was 24.1 kg/m2. No participants withdrew
from the study.
Pharmacokinetic endpoints
Figure 1 shows the mean plasma concentrations of the
two test and one reference ibuprofen formulations. The
mean values for Cmax, AUC0-t and AUC0-inf and the median
values for Tmax are presented in Table 2. Administration of
sodium ibuprofen resulted in a significantly shorter time
to peak plasma concentration (Tmax), compared with
standard ibuprofen (median 35 min vs 90 min; P  <
0.0002). Tmax for sodium ibuprofen was on average 55
minutes shorter than with standard ibuprofen.
Although the Tmax for ibuprofen/poloxamer was on aver-
age 20 minutes shorter than that of the standard ibupro-
fen formulation, this difference was not statistically
significant (median 75 min vs 90 min; P = 0.1913). The
power in terms of Tmax for a P-value of 0.0002 was >99%
and for a P-value of 0.1913 was 31%.
The Cmax results obtained for the sodium ibuprofen for-
mulation and the standard ibuprofen formulation were
41.47 and 31.88 μg/mL, respectively (geometric LS
means). The ratio of the test/reference was 130.06% with
90% CIs of 118.86-142.32%. The Cmax obtained for the
ibuprofen/poloxamer tablets was 35.22 μg/mL. The ratio
of the test/reference was 110.48% with 90% CIs of
100.96-120.89%.
For overall extent of absorption, all three formulations
were equivalent, with test/standard formulation ratios of
both AUC0-inf and AUC0-t very close to 100%. The AUC0-t
values were 117.79 μg/h/mL, 120.55 μg/h/mL and 115.28
μg/h/mL for sodium ibuprofen, ibuprofen/poloxamer
and standard ibuprofen, respectively. The AUC0-inf values
were 119.73 μg/h/mL, 122.75 μg/h/mL and 117.71 μg/h/
mL for sodium ibuprofen, ibuprofen/poloxamer and
standard ibuprofen, respectively.
Spaghetti plot of Cmax Figure 3
Spaghetti plot of Cmax.BMC Clinical Pharmacology 2009, 9:19 http://www.biomedcentral.com/1472-6904/9/19
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Table 3 shows the ratios of the sodium ibuprofen/stand-
ard formulations and the ibuprofen/poloxamer/standard
formulations for partial AUC. Throughout the first hour
post dose, the partial AUCs for both the sodium ibupro-
fen and ibuprofen/poloxamer formulations were higher
than those for the standard ibuprofen formulation, with
the greatest test/standard formulation absorption ratio
occurring at 20 minutes for both test formulations (Table
3). The spaghetti plots provide individual subject infor-
mation per treatment, for each of the four derived phar-
macokinetic parameters (Figures 2, 3, 4 and 5). In general,
Cmax was found to be higher and Tmax was lower for
sodium ibuprofen than ibuprofen/poloxamer or standard
ibuprofen (Figures 2, 3, 4 and 5).
There were no serious adverse events and no withdrawals
from the study because of an adverse event. Three individ-
uals reported a total of four adverse events, three of which
were considered mild and one moderate, but none was
considered to be related to the study drugs.
Discussion
This study showed that the Tmax for the sodium ibuprofen
formulation was less than half that of the standard ibu-
profen acid formulation, suggesting that the rate of
absorption of sodium ibuprofen was twice as fast as that
of standard ibuprofen tablets. As expected, this increased
rate of absorption was accompanied by an increase in the
peak plasma concentration of ibuprofen. Furthermore,
the CI of the ratio of the sodium ibuprofen/standard ibu-
profen tablets for Cmax was outside the 80-125% limit
specified in the Committee for Proprietary Medicinal
Products (CPMP) guidelines [20] and the United States
Food and Drug Administration (US FDA) guidelines for
bioavailability and bioequivalence [21]. The fact that the
sodium ibuprofen formulation was not bioequivalent
with the standard ibuprofen acid formulation was
expected given the faster absorption of ibuprofen from the
sodium formulation. This is likely to be due to faster dis-
solution and more rapid availability of ibuprofen particles
for absorption, as suggested by Sorgel et al. [9].
Spaghetti plot of AUC0-t Figure 4
Spaghetti plot of AUC0-t.BMC Clinical Pharmacology 2009, 9:19 http://www.biomedcentral.com/1472-6904/9/19
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The literature suggests that the addition of poloxamer 407
to the ibuprofen acid formulation might have resulted in
a faster absorption of ibuprofen than from standard ibu-
profen formulation [15]. Although the time to reach the
peak plasma concentration was, on average, 20 minutes
faster with the ibuprofen/poloxamer tablets, this differ-
ence failed to achieve statistical significance. As it had
been anticipated that the difference in Tmax between the
ibuprofen acid and ibuprofen/poloxamer formulations
would be 40 minutes, the study was not sufficiently pow-
ered (i.e. 31% only) for the observed difference to be sta-
tistically significant. The CI of the ratio of the ibuprofen/
poloxamer to the standard ibuprofen tablets for Cmax was
within the 80-125% limit specified in the CPMP guide-
lines [20] and FDA guidelines [21]. As the CI of the ratio
of the ibuprofen/poloxamer to the standard ibuprofen
tablets for AUC also fell within this limit, the ibuprofen/
poloxamer and standard ibuprofen formulations can be
considered bioequivalent.
The differences between the sodium ibuprofen formula-
tion and the standard ibuprofen formulation would not
be expected to result in adverse clinical consequences in
terms of either safety or efficacy. In support of this, there
were no clinically significant safety findings in the present
study.
The data from this study show that the overall amount of
drug to which the participants were exposed was the same
for the three formulations. However, because of the faster
absorption of ibuprofen from the sodium ibuprofen for-
mulation compared with the standard formulation, it is
expected that an OTC dose of two 256 mg sodium ibupro-
fen tablets may provide faster onset of analgesia without
compromising safety or duration of analgesia. Previous
studies have demonstrated that the median time to mean-
ingful pain relief for ibuprofen arginate was half that of
the standard ibuprofen [6,13,14]. Because the Tmax for
sodium ibuprofen in this study (median: 35 min) was
found to be similar to ibuprofen arginate (mean: 33.6
min) [9], it can be expected that sodium ibuprofen would
induce analgesic effects with a similar onset of action as
ibuprofen arginate. Such a formulation would be a valua-
ble addition to the OTC choice currently available to indi-
viduals with acute pain. To this extent, a clinical trial was
Spaghetti plot of AUC0-inf Figure 5
Spaghetti plot of AUC0-inf.BMC Clinical Pharmacology 2009, 9:19 http://www.biomedcentral.com/1472-6904/9/19
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conducted to explore this and data are published sepa-
rately [22].
Conclusion
The sodium ibuprofen formulation is equivalent to stand-
ard ibuprofen in terms of extent of absorption, but its rate
of absorption, as measured by Tmax, is significantly faster
(i.e. it was absorbed twice as fast as standard ibuprofen)
and Cmax is significantly higher. However, the ibuprofen/
poloxamer formulation was bioequivalent to the standard
ibuprofen formulation. Therefore, it is expected that an
OTC dose of two 256 mg sodium ibuprofen tablets may
provide faster onset of analgesic benefit, without compro-
mising safety.
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